AU2015255714B2 - Anti-viral compounds, pharmaceutical compositions, and methods of use thereof - Google Patents

Anti-viral compounds, pharmaceutical compositions, and methods of use thereof Download PDF

Info

Publication number
AU2015255714B2
AU2015255714B2 AU2015255714A AU2015255714A AU2015255714B2 AU 2015255714 B2 AU2015255714 B2 AU 2015255714B2 AU 2015255714 A AU2015255714 A AU 2015255714A AU 2015255714 A AU2015255714 A AU 2015255714A AU 2015255714 B2 AU2015255714 B2 AU 2015255714B2
Authority
AU
Australia
Prior art keywords
virus
compound
compounds
formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015255714A
Other languages
English (en)
Other versions
AU2015255714A1 (en
Inventor
Kristin M. Bedard
Kerry W. Fowler
Shawn P. Iadonato
Shari KAISER
Ikenna MADU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kineta Inc
Original Assignee
Kineta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta Inc filed Critical Kineta Inc
Publication of AU2015255714A1 publication Critical patent/AU2015255714A1/en
Application granted granted Critical
Publication of AU2015255714B2 publication Critical patent/AU2015255714B2/en
Priority to AU2020201815A priority Critical patent/AU2020201815A1/en
Priority to AU2020204324A priority patent/AU2020204324A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2015255714A 2014-05-09 2015-05-08 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof Ceased AU2015255714B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020201815A AU2020201815A1 (en) 2014-05-09 2020-03-12 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
AU2020204324A AU2020204324A1 (en) 2014-05-09 2020-06-29 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461991418P 2014-05-09 2014-05-09
US61/991,418 2014-05-09
US201562177900P 2015-03-25 2015-03-25
US62/177,900 2015-03-25
PCT/US2015/030014 WO2015172099A1 (en) 2014-05-09 2015-05-08 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020201815A Division AU2020201815A1 (en) 2014-05-09 2020-03-12 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2015255714A1 AU2015255714A1 (en) 2016-10-20
AU2015255714B2 true AU2015255714B2 (en) 2019-12-12

Family

ID=54393071

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015255714A Ceased AU2015255714B2 (en) 2014-05-09 2015-05-08 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
AU2020201815A Abandoned AU2020201815A1 (en) 2014-05-09 2020-03-12 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
AU2020204324A Abandoned AU2020204324A1 (en) 2014-05-09 2020-06-29 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020201815A Abandoned AU2020201815A1 (en) 2014-05-09 2020-03-12 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
AU2020204324A Abandoned AU2020204324A1 (en) 2014-05-09 2020-06-29 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof

Country Status (9)

Country Link
US (3) US9884876B2 (enExample)
EP (1) EP3139920A4 (enExample)
JP (1) JP6419313B2 (enExample)
CN (1) CN106456615B (enExample)
AU (3) AU2015255714B2 (enExample)
CA (1) CA2948178A1 (enExample)
MX (2) MX2016014642A (enExample)
TW (1) TW201623265A (enExample)
WO (1) WO2015172099A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018252193B2 (en) 2017-04-14 2024-12-12 Tallac Therapeutics, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
CA3051422A1 (en) * 2018-08-09 2020-02-09 Kineta, Inc. Activators of the retinoic acid inducible gene "rig-i" pathway and methods of use thereof
TW202035426A (zh) * 2018-08-17 2020-10-01 美商奇尼塔公司 視黃酸誘導基因"rig-i"途徑之活化劑及其使用方法
JP2022506351A (ja) * 2018-11-02 2022-01-17 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Ｂ型肝炎ウイルス（ｈｂｖ）に対して活性を有する新規ウレア６，７－ジヒドロ－４ｈ－チアゾロ［５，４－ｃ］ピリジン
AU2020289560A1 (en) * 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
WO2021007283A1 (en) * 2019-07-09 2021-01-14 Regents Of The University Of Minnesota Potentiation of antiviral nucleobases as rna virus therapy
EP4037706A4 (en) * 2019-10-02 2023-09-13 University of Washington Compositions and methods for treatment of hepatitis b virus infection
US11920136B2 (en) 2020-02-28 2024-03-05 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
WO2021198980A1 (en) 2020-04-04 2021-10-07 Pfizer Inc. Methods of treating coronavirus disease 2019
WO2021205290A1 (en) 2020-04-05 2021-10-14 Pfizer Inc. Compounds and method of treating covid-19
CN114641485A (zh) 2020-04-05 2022-06-17 辉瑞大药厂 用于治疗covid-19的化合物和方法
WO2021205296A1 (en) 2020-04-05 2021-10-14 Pfizer Inc. Method of treating covid-19
JP2023524271A (ja) 2020-05-08 2023-06-09 ボルト バイオセラピューティクス、インコーポレーテッド エラスターゼ－基質ペプチドリンカーイムノコンジュゲート、及びそれらの使用
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
CN113831301B (zh) * 2020-06-08 2023-06-06 沈阳药科大学 苯并噻唑类衍生物及其用途
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
US20230339930A1 (en) 2020-07-11 2023-10-26 Pfizer Inc. Antiviral Heteroaryl Ketone Derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
EP4228631B1 (en) * 2020-10-15 2024-08-21 Baden-Württemberg Stiftung gGmbH Flavi-block: a pan-flavivirus inhibitor
CN116897155A (zh) * 2021-02-24 2023-10-17 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的苯并噻唑基双环[1.1.1]戊烷衍生物
CN117460738A (zh) * 2021-03-24 2024-01-26 阿纳韦克斯生命科学公司 冠状病毒感染的预防和治疗
WO2022208262A1 (en) 2021-03-30 2022-10-06 Pfizer Inc. Ether-linked antiviral compounds
TWI869780B (zh) 2022-03-02 2025-01-11 美商輝瑞大藥廠 用於篩檢人類個體之呼吸疾病、監測人類個體之呼吸病況以及提供決策支援之方法及電腦化系統
WO2024149990A1 (en) 2023-01-10 2024-07-18 Oxford University Innovation Limited Nirmatrelvir analogs as 3c like protease inhibitors for treating viral infections
WO2024252327A1 (en) 2023-06-09 2024-12-12 Pfizer Inc. Solid forms of n-(methoxycarbonyl)-3-methyl-l-valyl-(4 r)- n-{(1 s)-1-cyano-2-[(3 s)-2-oxopyrrolidin-3-yl]ethyl}-4-(trifluoromethyl)-l-prolinamide and solvates thereof
WO2025037206A1 (en) 2023-08-11 2025-02-20 Pfizer Inc. Deuterated antiviral compounds
WO2025040743A1 (en) 2023-08-22 2025-02-27 Univerza V Ljubljani Conjugated tlr7 and rig-i agonists
WO2025191272A1 (en) 2024-03-13 2025-09-18 Storm Therapeutics Ltd Inhibitory compounds
CN119707862B (zh) * 2025-02-24 2025-06-27 北京悦康科创医药科技股份有限公司 基于RLRs受体激动剂的疫苗佐剂脂质化合物、包含其的组合物及用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63179793A (ja) * 1987-01-22 1988-07-23 Fuji Photo Film Co Ltd 光学的情報記録媒体
US20080039629A1 (en) * 2003-10-17 2008-02-14 Rigel Pharmaceuticals, Inc. Benzothniazole compositions and their use as ubiquition ligation inhibitors
WO2009067613A1 (en) * 2007-11-21 2009-05-28 Abbott Laboratories Novel compounds as cannabinoid receptor ligands and uses thereof
WO2011106273A1 (en) * 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2013049407A2 (en) * 2011-09-30 2013-04-04 Kineta, Inc Anti-viral compounds
WO2014113492A2 (en) * 2013-01-15 2014-07-24 Kineta, Inc. Anti-viral compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1024316A (en) * 1911-07-29 1912-04-23 Singer Mfg Co Strip folding and guiding attachment for sewing-machines.
JPS53129036A (en) * 1977-04-18 1978-11-10 Fuji Photo Film Co Ltd Color photographic material
GB9923710D0 (en) 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
WO2004078115A2 (en) * 2003-02-28 2004-09-16 Viropharma, Incorporated Benzothiazole compounds, compositions and methods for treatment and prophylaxis of rotavirus infections and associated diseases
WO2012155352A1 (en) 2011-05-19 2012-11-22 Eli Lilly And Company Dihydroisoxazole compounds, parasiticidal uses and formulations thereof
CN103193770B (zh) * 2013-03-20 2015-10-28 中国人民解放军第二军医大学 取代苯并噻唑类抗真菌化合物及其制备方法与应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63179793A (ja) * 1987-01-22 1988-07-23 Fuji Photo Film Co Ltd 光学的情報記録媒体
US20080039629A1 (en) * 2003-10-17 2008-02-14 Rigel Pharmaceuticals, Inc. Benzothniazole compositions and their use as ubiquition ligation inhibitors
WO2009067613A1 (en) * 2007-11-21 2009-05-28 Abbott Laboratories Novel compounds as cannabinoid receptor ligands and uses thereof
WO2011106273A1 (en) * 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2013049407A2 (en) * 2011-09-30 2013-04-04 Kineta, Inc Anti-viral compounds
WO2014113492A2 (en) * 2013-01-15 2014-07-24 Kineta, Inc. Anti-viral compounds

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 1024533-85-4. Date Entered STN: 1 June 2008. 2-Naphthalenecarboxamide, N-[6-[(ethylmethylamino)sulfonyl]-2-benzothiazolyl]- *
CAS Registry Number 1173428-91-5. Date Entered STN: 7 August 2009. 2-Naphthalenecarboxamide, 3-methoxy-N-(3-propyl-2(3H)-benzothiazolylidene)- *
CAS Registry Number 1173494-34-2. Date Entered STN: 7 August 2009. 1-Naphthalenecarboxamide, N-(3-propyl-2(3H)-benzothiazolylidene)- *
CAS Registry Number 1296552-81-2. Date Entered STN: 18 May 2011. 2-Naphthalenecarboxamide, N-2-benzothiazolyl-N-(2-methoxyethyl)- *
CAS Registry Number 361482-13-5. Date Entered STN: 11 October 2001. Benzamide, 4-[(2,6-dimethyl-4-morpholinyl)sulfonyl]-N-(7-methylbenzo[1,2-d:3,4-d']bisthiazol-2-yl)- *
CAS Registry Number 441290-37-5. Date Entered STN: 31 July 2002. 2-Naphthalenecarboxamide, 3-methoxy-N-(7-methylbenzo[1,2-d:3,4-d']bisthiazol-2-yl)- *
CAS Registry Number 476642-17-8. Date Entered STN: 18 December 2002. Benzamide, 4-[[bis(2-cyanoethyl)amino]sulfonyl]-N-(7-methylbenzo[1,2-d:3,4-d']bisthiazol-2-yl)- *
CAS Registry Number 476642-19-0. Date Entered STN: 18 December 2002. Benzo[b]thiophene-2-carboxamide, 3-chloro-N-(7-methylbenzo[1,2-d:3,4-d']bisthiazol-2-yl)- *
CAS Registry Number 867041-50-7. Date Entered STN: 9 November 2005. Benzamide, N-(7-methylbenzo[1,2-d:3,4-d']bisthiazol-2-yl)-4-(4-morpholinylsulfonyl)- *
Koehler, M. F. T. et al, "Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL", ACS Med. Chem. Lett., 2014, Vol. 5, No. 6, pp 662-667 *
Pubchem, "National Center for Biotechnology Information. PubChem Compound Database; CID=3447812", (2005-09-08), URL: https://pubchem.ncbi.nlm.nih.gov/compound/3447812, (2017-09-08) *
Pubchem, "National Center for Biotechnology Information. PubChem Compound Database; CID=4025738", (2005-09-11), URL: https://pubchem.ncbi.nlm.nih.gov/compound/4025738, (2017-09-08) *
Pubchem, "National Center for Biotechnology Information. PubChem Compound Database; CID=40613063", (2009-05-30), URL: https://pubchem.ncbi.nlm.nih.gov/compound/40613063, (2017-09-08) *
Pubchem, "National Center for Biotechnology Information. PubChem Compound Database; CID=4186962", (2005-09-13), URL: https://pubchem.ncbi.nlm.nih.gov/compound/4186962, (2017-09-08) *
Pubchem, "National Center for Biotechnology Information. PubChem Compound Database; CID=5050525", (2005-09-18), URL: https://pubchem.ncbi.nlm.nih.gov/compound/5050525, (2017-09-08) *
PubChem, (2005-07-10), Database accession no. 1160318 *
PubChem, (2005-07-11), Database accession no. CID-1548136 *
PubChem, (2005-09-13), Database accession no. 4219163 *
Uehara, T. et al, "Palladium-Catalyzed C_H and C_N Arylation of Aminothiazoles with Arylboronic Acids", Asian J. Org. Chem., 2013, Vol. 2, No. 11, pp 938-942 *

Also Published As

Publication number Publication date
CA2948178A1 (en) 2015-11-12
MX2020005187A (es) 2020-08-20
US9884876B2 (en) 2018-02-06
CN106456615A (zh) 2017-02-22
JP6419313B2 (ja) 2018-11-07
EP3139920A1 (en) 2017-03-15
WO2015172099A1 (en) 2015-11-12
MX2016014642A (es) 2017-05-25
US20200270274A1 (en) 2020-08-27
CN106456615B (zh) 2020-10-27
AU2020201815A1 (en) 2020-04-02
JP2017515901A (ja) 2017-06-15
US20190002477A1 (en) 2019-01-03
EP3139920A4 (en) 2017-11-01
US20170057978A1 (en) 2017-03-02
AU2020204324A1 (en) 2020-07-16
TW201623265A (zh) 2016-07-01
AU2015255714A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
AU2015255714B2 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
US20160102099A1 (en) Anti-viral compounds
US20160122312A1 (en) Anti-viral compounds, pharmaceutical compositions and methods of use thereof
AU2017254812B2 (en) Anti-viral compounds
WO2016073947A1 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
US9073946B2 (en) Anti-viral compounds
WO2016057518A1 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
OA19256A (en) Anti-Viral Compounds.
HK1199029B (en) Anti-viral compounds
NZ622636B2 (en) Substituted benzothiazole compounds and their use in the treatment of viral infections

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired